Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Eisai Co., Ltd. (Lenvima Oncology Alliance) by Year
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Net R&D cost-sharing expense ($M) ($M)
Merck Eisai Co., Ltd. (Lenvima Oncology Alliance): $11M in FY2025, down 47.6% from a year earlier. That is the lowest of the 8 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Eisai Co., Ltd. (Lenvima Oncology Alliance) — Net R&D cost-sharing expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11 | -47.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 21 | -68.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 66 | -51.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 136 | -21.4% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 173 | -6.5% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 185 | -2.1% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 189 | -86.5% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 1,400 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). Merck Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M), annual FY2018–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-eisai-rd
See every metric in the Merck KPI table. Data updated Oct 26, 2026.